UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 139

Sortiert nach

Pharmacokinetic drug–drug interaction between olaparib and apixaban: a case report

Cancer chemotherapy and pharmacology, 2024-05, Vol.93 (5), p.519-521

2024

Link zum Volltext

Verfügbarkeit prüfen

Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies

European journal of epidemiology, 2019-02, Vol.34 (2), p.173-190

2019

Link zum Volltext

Verfügbarkeit prüfen

The Leave Safe with DOACs Randomized Controlled Trial

Journal of general internal medicine : JGIM, 2024-04, Vol.39 (5), p.880-880

Kapoor, Alok

2024

Link zum Volltext

Verfügbarkeit prüfen

Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study

Journal of thrombosis and thrombolysis, 2019-08, Vol.48 (2), p.250-255

2019

Link zum Volltext

Verfügbarkeit prüfen

The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding

Journal of thrombosis and thrombolysis, 2020-05, Vol.49 (4), p.636-643

2020

Link zum Volltext

Verfügbarkeit prüfen

Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis

Cardiovascular drugs and therapy, 2021-10, Vol.35 (5), p.975-986

2021

Link zum Volltext

Verfügbarkeit prüfen

Plasma levels of direct oral anticoagulants in atrial fibrillation patients at the time of embolic stroke: a pilot prospective multicenter study

European journal of clinical pharmacology, 2022-04, Vol.78 (4), p.557-564

2022

Link zum Volltext

Verfügbarkeit prüfen

Comparative effectiveness and safety of direct oral anticoagulants compared to warfarin in morbidly obese patients with acute venous thromboembolism: systematic review and a meta-analysis

Journal of thrombosis and thrombolysis, 2021-02, Vol.51 (2), p.388-396

2021

Link zum Volltext

Verfügbarkeit prüfen

Massive Post-polypectomy Bleeding in a Patient on Apixaban Reversed with Andexanet Alfa

Digestive diseases and sciences, 2023-08, Vol.68 (8), p.3199-3200

2023

Link zum Volltext

Verfügbarkeit prüfen

Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis

Journal of thrombosis and thrombolysis, 2021-02, Vol.51 (2), p.419-429

2021

Link zum Volltext

Verfügbarkeit prüfen

Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage

Neurocritical care, 2021-08, Vol.35 (1), p.255-261

2021

Link zum Volltext

Verfügbarkeit prüfen

Predictors for a high apixaban level in elderly patients with atrial fibrillation prescribed reduced dose of apixaban

European journal of clinical pharmacology, 2021-11, Vol.77 (11), p.1757-1758

2021

Link zum Volltext

Verfügbarkeit prüfen

Perioperative Management in Patients with Atrial Fibrillation Treated with Non-Vitamin K Antagonist Oral Anticoagulants Undergoing Minor Bleeding Risk Procedure: Rationale and Protocol for the PERIXa Study

Translational behavioral medicine, 2024-05, Vol.20 (6), p.231-244

2024

Link zum Volltext

Verfügbarkeit prüfen

Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage

Journal of thrombosis and thrombolysis, 2023-04, Vol.55 (3), p.519-526

2023

Link zum Volltext

Verfügbarkeit prüfen

Real-world clinical outcomes among US Veterans with oral factor xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate

Journal of thrombosis and thrombolysis, 2023-07, Vol.56 (1), p.137-146

2023

Link zum Volltext

Verfügbarkeit prüfen

Retrospective review of Andexanet Alfa versus 4-Factor Prothrombin Complex Concentrate for reversal of DOAC-Associated Intracranial Hemorrhage

Journal of thrombosis and thrombolysis, 2023-01, Vol.55 (1), p.149-155

2023

Link zum Volltext

Verfügbarkeit prüfen

Severe Bleeding Risk of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Stroke Prevention and Treatment in Patients with Atrial Fibrillation: A Systematic Review and Network Meta-Analysis

Cardiovascular drugs and therapy, 2023-04, Vol.37 (2), p.363-377

2023

Link zum Volltext

Verfügbarkeit prüfen

The Impairment in Kidney Function in the Oral Anticoagulation Era. A Pathophysiological Insight

Cardiovascular drugs and therapy, 2021-06, Vol.35 (3), p.505-519

2021

Link zum Volltext

Verfügbarkeit prüfen

Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Obese Patients with Atrial Fibrillation

Cardiovascular drugs and therapy, 2021-04, Vol.35 (2), p.261-272

2021

Link zum Volltext

Verfügbarkeit prüfen

Comparison of warfarin versus DOACs in patients with concomitant indication for oral anticoagulation undergoing TAVI; results from the ATLAS registry

Journal of thrombosis and thrombolysis, 2020-07, Vol.50 (1), p.82-89

2020

Link zum Volltext

Verfügbarkeit prüfen

Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate

Internal and emergency medicine, 2019-03, Vol.14 (2), p.265-269

Sheikh-Taha, Marwan

2019

Link zum Volltext

Verfügbarkeit prüfen

Characterization of an andexanet alfa administration protocol guided by drug-specific quantitative anti-Xa assays

Journal of thrombosis and thrombolysis, 2024-02, Vol.57 (2), p.285-292

2024

Link zum Volltext

Verfügbarkeit prüfen

PrevAleNce and Associated factors of inappropriaTe dosing of direct Oral anticoaguLants In pAtients with Atrial Fibrillation: the ANATOLIA-AF Study

Cardiovascular drugs and therapy, 2024-06, Vol.38 (3), p.581-599

2024

Link zum Volltext

Verfügbarkeit prüfen

Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms

Annals of hematology, 2021-08, Vol.100 (8), p.2015-2022

2021

Link zum Volltext

Verfügbarkeit prüfen

Comparison of Traumatic Intracranial Hemorrhage Expansion and Outcomes Among Patients on Direct Oral Anticoagulants Versus Vitamin k Antagonists

Neurocritical care, 2020-04, Vol.32 (2), p.407-418

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 139

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(137)
Mit Volltextzugriff
(139)

Publikationsform

Artikel
(139)

Sprache

Englisch
(136)
Japanisch
(17)
Deutsch
(4)

Erscheinungsjahr

n.n

Thema

Humans
(139)
Life Sciences & Biomedicine
(134)
Science & Technology
(134)
Medicine
(121)
Medicine & Public Health
(121)
Cardiovascular System & Cardiology
(85)
Cardiac & Cardiovascular Systems
(82)
Cardiology
(82)
Anticoagulants
(81)
Factor Xa Inhibitors - Adverse Effects
(74)
Anticoagulants - Adverse Effects
(72)
Female
(66)
Male
(62)
Peripheral Vascular Disease
(62)
Hemorrhage - Chemically Induced
(59)
Hematology
(58)
Aged
(51)
Bleeding
(50)
Anticoagulants - Therapeutic Use
(45)
Factor Xa Inhibitors - Therapeutic Use
(45)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Pharmacokinetic drug–drug interaction between olaparib and apixaban: a case report

Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies

The Leave Safe with DOACs Randomized Controlled Trial

Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study

The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding

Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis

Plasma levels of direct oral anticoagulants in atrial fibrillation patients at the time of embolic stroke: a pilot prospective multicenter study

Comparative effectiveness and safety of direct oral anticoagulants compared to warfarin in morbidly obese patients with acute venous thromboembolism: systematic review and a meta-analysis

Massive Post-polypectomy Bleeding in a Patient on Apixaban Reversed with Andexanet Alfa

Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis

Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage

Predictors for a high apixaban level in elderly patients with atrial fibrillation prescribed reduced dose of apixaban

Perioperative Management in Patients with Atrial Fibrillation Treated with Non-Vitamin K Antagonist Oral Anticoagulants Undergoing Minor Bleeding Risk Procedure: Rationale and Protocol for the PERIXa Study

Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage

Real-world clinical outcomes among US Veterans with oral factor xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate

Retrospective review of Andexanet Alfa versus 4-Factor Prothrombin Complex Concentrate for reversal of DOAC-Associated Intracranial Hemorrhage

Severe Bleeding Risk of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Stroke Prevention and Treatment in Patients with Atrial Fibrillation: A Systematic Review and Network Meta-Analysis

The Impairment in Kidney Function in the Oral Anticoagulation Era. A Pathophysiological Insight

Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Obese Patients with Atrial Fibrillation

Comparison of warfarin versus DOACs in patients with concomitant indication for oral anticoagulation undergoing TAVI; results from the ATLAS registry

Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate

Characterization of an andexanet alfa administration protocol guided by drug-specific quantitative anti-Xa assays

PrevAleNce and Associated factors of inappropriaTe dosing of direct Oral anticoaguLants In pAtients with Atrial Fibrillation: the ANATOLIA-AF Study

Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms

Comparison of Traumatic Intracranial Hemorrhage Expansion and Outcomes Among Patients on Direct Oral Anticoagulants Versus Vitamin k Antagonists

Aktive Filter

Suchergebnisse filtern